These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 16197454)

  • 1. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
    Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
    Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
    Seropian S; Bahceci E; Cooper DL
    Bone Marrow Transplant; 2003 Oct; 32(8):763-9. PubMed ID: 14520419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
    Pavletic ZS; Arrowsmith ER; Bierman PJ; Goodman SA; Vose JM; Tarantolo SR; Stein RS; Bociek G; Greer JP; Wu CD; Kollath JP; Weisenburger DD; Kessinger A; Wolff SN; Armitage JO; Bishop MR
    Bone Marrow Transplant; 2000 Apr; 25(7):717-22. PubMed ID: 10745256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
    Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
    Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms.
    Murashige N; Kami M; Kishi Y; Kim SW; Takeuchi M; Matsue K; Kanda Y; Hirokawa M; Kawabata Y; Matsumura T; Kusumi E; Hirabayashi N; Nagafuji K; Suzuki R; Takeuchi K; Oshimi K
    Br J Haematol; 2005 Aug; 130(4):561-7. PubMed ID: 16098071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.